clinical trial · NCT05152147
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Gastric NeoplasmsGastroesophageal AdenocarcinomaEsophageal AdenocarcinomaZanidatamabTislelizumabTrastuzumabCapecitabineOxaliplatinCisplatin5-Fluorouracil
brief summary
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach and esophageal cancers that are no longer treatable with surgery (unresectable) or chemoradiation, and/or have grown or spread to other parts of the body (metastatic).
started
Dec 2, 2021
primary completion
Jul 31, 2026
completion
Jul 31, 2027
last updated
Apr 17, 2026
official title
A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol